Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway

Cardiovascular risk factors have attracted increasing attention in recent years with the acceleration of population aging, amongst which cardiac hypertrophy is the initiating link to heart failure. Pirfenidone is a promising agent for the treatment of idiopathic pulmonary fibrosis and has recently p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhenhuan, Zhou, Haiwen, Huang, Xiantao, Wang, Shaoyun, Ouyang, Xiaochao, Wang, Yunxia, Cao, Qianqiang, Yang, Liu, Tao, Yu, Lai, Hengli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276057/
https://www.ncbi.nlm.nih.gov/pubmed/35609321
http://dx.doi.org/10.1080/21655979.2022.2073145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276057/
https://www.ncbi.nlm.nih.gov/pubmed/35609321
http://dx.doi.org/10.1080/21655979.2022.2073145

Ejemplares similares